Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Accured Expenses (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Change in Accured Expenses data on record, last reported at $23.5 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 77.9% year-over-year to $23.5 million; the TTM value through Dec 2025 reached $50.0 million, up 56.23%, while the annual FY2025 figure was $50.0 million, 56.23% up from the prior year.
  • Change in Accured Expenses reached $23.5 million in Q4 2025 per ARQT's latest filing, up from $5.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $23.5 million in Q4 2025 and bottomed at -$5.5 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $5.0 million, with a median of $4.5 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 1711.17% in 2021, then crashed 234.77% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $11.7 million in 2021, then plummeted by 94.73% to $616000.0 in 2022, then skyrocketed by 860.55% to $5.9 million in 2023, then surged by 122.8% to $13.2 million in 2024, then soared by 77.9% to $23.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $23.5 million in Q4 2025, $5.6 million in Q3 2025, and $21.2 million in Q2 2025.